Grail (NASDAQ:GRAL) stock has been highly volatile in 2026, and that trend looks set to continue next year as well. Management expects its multi-cancer early detection (MCED) test, Galleri, to be approved in the first quarter of 2027, but that's only part of the story. Here's what investors need…